Analysis and management of a case of immune-related liver damage and thrombocytopenia caused by sintilimab
Objective To investigate the causes,treatment and pharmaceutical care of immunotherapy-related liver injury and thrombocytopenia caused by sintilimab,and to ensure the safety and effectiveness of immunotherapy in patients.Methods Clinical pharmacists participated in the whole process of treatment of immunotherapy related liver injury and thrombocytopenia induced by sintilimab,analyzed the identification,mechanism,treatment methods and subsequent treatment options of adverse reactions,and provided pharmaceutical care.Results Sintilimab could induce immunotherapy-related liver injury and thrombocytopenia.Although the incidence of adverse reactions of immunotherapy is low,we should timely perform baseline assessment for patients receiving immunotherapy and at potential risk of anti-tumor treatment,while doing a good job in the management of disease-related risk factors,and cooperate with clinicians in the assessment,intervention and treatment of related diseases.The above measures can reduce the prognostic risk of adverse reactions in cancer patients.Conclusion Clinical pharmacists actively monitor and participate in the analysis of adverse reactions such as hematotoxicity and hepatotoxicity associated with cancer immunotherapy.By giving pharmaceutical care and treatment plan analysis,it can reduce the risk of prognosis of adverse tumor reactions,provide medication reference and guidance for patients undergoing clinical immunotherapy,and effectively improve the effectiveness and safety of drug treatment for patients
NETL
NSTL
万方数据
